Geneva Capital Management LLC Has $51.58 Million Position in Axon Enterprise, Inc $AXON

Geneva Capital Management LLC cut its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 4.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 91,999 shares of the biotechnology company’s stock after selling 4,729 shares during the quarter. Geneva Capital Management LLC owned 0.11% of Axon Enterprise worth $51,576,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Edgewood Management LLC bought a new position in Axon Enterprise in the 4th quarter valued at approximately $846,516,000. Wellington Management Group LLP boosted its position in Axon Enterprise by 326.9% in the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after buying an additional 1,179,038 shares in the last quarter. Norges Bank bought a new stake in shares of Axon Enterprise during the fourth quarter worth $515,764,000. Styrax Capital LP bought a new stake in shares of Axon Enterprise during the first quarter worth $84,938,000. Finally, Sands Capital Management LLC increased its holdings in shares of Axon Enterprise by 11.6% during the fourth quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock worth $914,047,000 after buying an additional 167,095 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Price Performance

AXON stock opened at $612.83 on Friday. The company has a market capitalization of $49.79 billion, a P/E ratio of 254.29, a PEG ratio of 12.50 and a beta of 1.39. The company has a fifty day moving average price of $526.06 and a 200-day moving average price of $474.40. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $794.29.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.84 by $0.04. The company had revenue of $904.39 million for the quarter, compared to analysts’ expectations of $876.42 million. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. Axon Enterprise’s revenue for the quarter was up 35.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.12 earnings per share. As a group, equities analysts expect that Axon Enterprise, Inc will post 2.04 EPS for the current year.

Insider Activity

In other news, insider Isaiah Fields sold 2,000 shares of the stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $400.00, for a total value of $800,000.00. Following the completion of the sale, the insider owned 52,813 shares of the company’s stock, valued at approximately $21,125,200. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Patrick W. Smith sold 20,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $10,000,000.00. Following the transaction, the chief executive officer owned 3,060,997 shares of the company’s stock, valued at $1,530,498,500. This trade represents a 0.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 68,989 shares of company stock worth $36,016,932. 4.20% of the stock is owned by corporate insiders.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Northland Securities raised several future earnings estimates. The firm lifted its FY2027 EPS forecast to $6.49 from $5.53 and increased estimates for Q1–Q4 2027, as well as Q3 2026. The revisions suggest stronger anticipated earnings from Axon’s connected-device, software, AI and public-safety technology businesses.
• Positive Sentiment: Axon raised its 2026 revenue-growth outlook to 32%–34%. Management cited strong momentum in connected devices, international demand, counter-drone products and AI-enabled software, supported by approximately $15.1 billion in future contracted bookings. Axon Enterprise Is Up 17.8% After Raising 2026 Revenue Outlook
• Neutral Sentiment: Recent quarterly results exceeded expectations. Second-quarter revenue increased 35.3% year over year to $904.4 million and topped consensus, while adjusted EPS also beat estimates. However, reported net income and diluted EPS declined, highlighting the trade-off between rapid expansion and near-term profitability. The 5 Most Interesting Analyst Questions From Axon’s Q2 Earnings Call
• Negative Sentiment: Northland reduced its FY2026 EPS forecast to $3.12 from $3.26 and cut its Q4 2026 estimate to $1.29 from $1.55. These downgrades indicate some near-term earnings pressure even though longer-term forecasts improved.
• Negative Sentiment: Insider selling added pressure. A report attributed a 6.5% decline to recent insider sales, which can raise concerns about valuation or management’s view of near-term upside. Axon Enterprise Trading Down Following Insider Selling
• Negative Sentiment: Valuation and margins remain risks. With a very high earnings multiple and reported margin contraction, investors may be demanding clearer evidence that revenue growth will translate into sustained profit growth.

Analysts Set New Price Targets

AXON has been the subject of a number of research reports. Royal Bank Of Canada reiterated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, July 21st. Morgan Stanley boosted their price objective on Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Needham & Company LLC reaffirmed a “buy” rating on shares of Axon Enterprise in a report on Thursday, August 6th. Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 10th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $715.00 price target on shares of Axon Enterprise in a research note on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $730.92.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.